Polymers for reversing heparin-based anticoagulation

• US 8,637,008 B2
• Filed: 04/27/2012
• Issued: 01/28/2014
• Est. Priority Date: 06/01/2011
• Status: Expired due to Fees

• Current Assignee: University of British Columbia
• Original Assignee: University of British Columbia
• Inventors: Kizhakkedathu, Jayachandran N., Shenoi, Rajesh A., Carter, Cedric J., Brooks, Donald E.
• Primary Examiner(s): Sullivan, Daniel
• Assistant Examiner(s): Cao, Ping
• Application Number:
  US13/458,899
• Publication Number:
  US 20120308546A1
• Time in Patent Office: 641 Days
• Field of Search: None
• US Class Current: 424/94.5
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 31/795 Polymers containing sulfur
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61M 1/3675 Deactivation
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0021 removed from and reintroduced into the body, e.g. after treatment
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/0478 Heparin
• CPC Class Codes: B01D 15/36 involving ionic interaction
• CPC Class Codes: C08G 2340/00 Filter material
• CPC Class Codes: C08G 73/024 Polyamines containing oxygen in the form of ether bonds in the main chain
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims

1. A method of counteracting heparin in a subject, the method comprising administering a heparin binding polymer to a subject, the heparin binding polymer comprising:

a first dendritic polyol; and

one or more cationic moieties attached to the first dendritic polyol,

wherein the polymer comprises at least one of;

a) the structure of Formula (I);

2. The method of claim 1, wherein the heparin binding polymer further comprises polyethylene glycol covalently attached to the heparin binding polymer.

3. The method of claim 2, wherein the cationic moiety is an amine group.

4. The method of claim 3, wherein the amine group is a tetra-amine group, a hexa-amine group, or a deca-amine group.

5. The method of claim 2, further comprising identifying a subject who has received an excess amount of heparin, wherein the identifying occurs before the heparin binding polymer is administered to the subject.

6. The method of claim 2, wherein an excess amount of heparin was administered to the subject.

7. The method of claim 6, wherein the excess amount of heparin was administered for the maintenance of an intravenous catheter.

8. The method of claim 6, wherein the excess amount of heparin was administered to treat one or more of the following:

acute coronary syndrome, atrial fibrillation, cardiac bypass, extracorporeal membrane oxygenation, pancreatitis, hemofiltration, or burns.

9. The method of claim 1, further comprising identifying a subject that would benefit from reducing a level of exogenous heparin that is present in the subject'"'"'s blood.

10. The method of claim 9, wherein the subject will benefit from an accelerated removal of exogenous heparin from the subject.

11. The method of claim 2, wherein the method is performed in vivo.

12. The method of claim 2, wherein the method is performed ex vivo.

13. The method of claim 1, wherein the subject is a human.

14. The method of claim 1, wherein the subject is a dog, a cat, a horse, a cow, a pig, a mouse, a rat, a rabbit, a monkey, or a guinea pig.

15. The method of claim 1, wherein the heparin binding polymer is administered subcutaneously.

16. The method of claim 1, wherein the heparin binding polymer is administered intravenously.

17. The method of claim 1, wherein the heparin binding polymer binds to heparin selected from at least one of:

unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

18. The method of claim 17, wherein the heparin binding polymer binds to fondaparinux.

19. The method of claim 6, wherein the excess amount of heparin is selected from selected from at least one of:

unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

20. The method of claim 19, wherein the excess amount of heparin is fondaparinux.